Literature DB >> 16075198

[Aftercare in testicular cancer is worthwhile. Recurrences are curable].

T S Pottek1, K-P Dieckmann.   

Abstract

Patients with germ cell tumours of the testis can have an extremely favourable chance of cure when compared to other malignancies. Therapeutic problems may arise with recurrent disease. High tumour burden can result when relapses are diagnosed too late and the prognosis will deteriorate, consecutively, even in spite of intensified therapeutic endeavours. Apart from early detection of recurrent disease, the follow-up schedule of germ cell cancer aims to identify and manage treatment-related morbidities, e.g. vascular problems and second neoplasms, respectively. Follow-up examinations should be tailored to the individual situation taking into account the particular risk of relapse based on histology, stage and treatment previously applied. In light of the rarity of the disease and according to the complexity of managing this malignancy, follow-up should be conducted by particularly experienced institutions.

Entities:  

Mesh:

Year:  2005        PMID: 16075198     DOI: 10.1007/s00120-005-0881-x

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  23 in total

Review 1.  Regular review: Managing testicular cancer.

Authors:  D Dearnaley; R Huddart; A Horwich
Journal:  BMJ       Date:  2001-06-30

2.  Late relapse of testicular germ cell neoplasms: a descriptive analysis of 122 cases.

Authors:  Klaus-Peter Dieckmann; Peter Albers; Johannes Classen; Maike De Wit; Uwe Pichlmeier; Oliver Rick; Ulrich Müllerleile; Markus Kuczyk
Journal:  J Urol       Date:  2005-03       Impact factor: 7.450

Review 3.  [Late toxicity after chemotherapy of malignant testicular tumors].

Authors:  A Jakob; C Kollmannsberger; L Kanz; C Bokemeyer
Journal:  Urologe A       Date:  1998-11       Impact factor: 0.639

Review 4.  Treatment of testicular germ-cell cancer: a cochrane evidence-based systematic review.

Authors:  M D Shelley; K Burgon; M D Mason
Journal:  Cancer Treat Rev       Date:  2002-10       Impact factor: 12.111

5.  International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group.

Authors: 
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

6.  False-negative biopsies for the diagnosis of testicular intraepithelial neoplasia (TIN)--an update.

Authors:  K-P Dieckmann; V Loy
Journal:  Eur Urol       Date:  2003-05       Impact factor: 20.096

Review 7.  Management of recurrence and follow-up strategies for patients with nonseminoma testis cancer.

Authors:  Michael A S Jewett; Arthur Grabowski; James McKiernan
Journal:  Urol Clin North Am       Date:  2003-11       Impact factor: 2.241

Review 8.  Long-term sequelae after cancer therapy--survivorship after treatment for testicular cancer.

Authors:  Sophie D Fosså
Journal:  Acta Oncol       Date:  2004       Impact factor: 4.089

9.  Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer.

Authors:  C Bokemeyer; C C Berger; J T Hartmann; C Kollmannsberger; H J Schmoll; M A Kuczyk; L Kanz
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

10.  Survival of patients with nonseminomatous germ cell cancer: a review of the IGCC classification by Cox regression and recursive partitioning.

Authors:  M R van Dijk; E W Steyerberg; S P Stenning; E Dusseldorp; J D F Habbema
Journal:  Br J Cancer       Date:  2004-03-22       Impact factor: 7.640

View more
  3 in total

Review 1.  [Follow-up of testicular germ cell tumors-historical aspects and current recommendations].

Authors:  Klaus-Peter Dieckmann; Christian Guido Ruf; Raphael Gübitz; Christian Wülfing; Friedemann Zengerling
Journal:  Urologe A       Date:  2022-04-06       Impact factor: 0.639

2.  Serotonin used as prognostic marker of urological tumors.

Authors:  Nina Jungwirth; Lothar Haeberle; Karl Michael Schrott; Bernd Wullich; Frens Steffen Krause
Journal:  World J Urol       Date:  2008-06-26       Impact factor: 4.226

3.  [Secondary prevention after urological tumor diseases. Focusing on the kidneys, testes, and bladder].

Authors:  M J Mathers; D A Lazica; T Klotz; F Sommer; S Roth
Journal:  Urologe A       Date:  2007-06       Impact factor: 0.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.